Mint Tower Capital Management B.V. Takes $1.53 Million Position in Kenvue Inc. $KVUE

Mint Tower Capital Management B.V. bought a new position in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 80,000 shares of the company’s stock, valued at approximately $1,529,000.

Several other large investors have also recently modified their holdings of the stock. Elyxium Wealth LLC purchased a new stake in shares of Kenvue in the fourth quarter valued at $26,000. Johnson Financial Group Inc. bought a new stake in shares of Kenvue in the 2nd quarter worth about $26,000. MV Capital Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth about $28,000. CoreCap Advisors LLC grew its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares during the last quarter. Finally, Reflection Asset Management bought a new position in Kenvue during the 4th quarter valued at about $32,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.3%

Shares of NYSE:KVUE opened at $19.15 on Friday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $20.82. The stock has a market cap of $36.78 billion, a P/E ratio of 22.01, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47. The business’s 50 day moving average is $19.16 and its 200 day moving average is $18.25. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same period last year, the firm earned $0.29 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a $0.21 dividend. The ex-dividend date was Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio is presently 96.55%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KVUE. UBS Group decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Finally, Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.